-
Mashup Score: 1cAttendee - 1 year(s) agoSource: cattendee.abstractsonline.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 5cAttendee - 1 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0cAttendee - 1 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0cAttendee - 1 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2cAttendee - 1 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3cAttendee - 1 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1cAttendee - 1 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0cAttendee - 2 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1cAttendee - 2 year(s) agoSource: cattendee.abstractsonline.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 3cAttendee - 2 year(s) agoSource: cattendee.abstractsonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Benmelstobart and anlotinib + chemotherapy improve PFS (6.9 months vs. 4.2 months) and OS (19.3 months vs. 11.9 months) in Extensive stage SCLC https://t.co/6XDtGDpwzM https://t.co/1Ioqlo1fu0